Clinical Trial Update: Efficacy and Safety of Oral HBI-8000 in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating oral HBI-8000 in relapsed or refractory Peripheral T-Cell Lymphoma has completed, with efficacy and safety results posted on 2024-09-19…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Peripheral T-cell Lymphoma

Drugs mentioned

• HBI-8000

Snippet

Sponsor: HUYABIO International, LLC. | Conditions: Peripheral T-Cell Lymphoma (PTCL) | Phase 2 | Status: COMPLETED | Results posted: 2024-09-19